Bronchial asthma in the elderly: diagnostic features, clinical course, and treatment approaches
Gaynitdinova V.V., Aleksandrova A.A., Evdokimova S.A.
Globally, the number of elderly patients is growing. It is expected that by 2050, this age group will account for 17% of the global population. As the number of patients over 65 years of age increases, understanding of disease development and clinical features, treatment approaches, and the issue of patient comorbidity are changing. Bronchial asthma in the elderly remains poorly understood. Determining the exact prevalence of bronchial asthma in the elderly is difficult. However, several studies have shown that the prevalence of bronchial asthma in the elderly ranges from 1.8 to 10.9%, is more common in men, and tends to increase over time. This is primarily due to the lack of universal diagnostic criteria in older adults, comorbidity, immunosenescence, heterogeneity of clinical and functional manifestations of the disease, poor patient perception of symptoms, difficulty conducting functional tests, and the lack of response to standard therapy. Therefore, further study of the characteristics of bronchial asthma in this cohort is necessary to improve diagnosis, treatment, and quality of life in elderly patients.
For citations: Gaynitdinova V.V., Aleksandrova A.A., Evdokimova S.A. Bronchial asthma in the elderly: diagnostic features, clinical course, and treatment approaches. Pharmateca. 2025;32(9):24-30. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2025.9.24-30
Authors’ contribution: Concept of the article – V.V. Gaynitdinova. Literature review – A.A. Aleksandrova, V.V. Gaynitdinova, S.A. Evdokimova. Editing – V.V. Gaynitdinova, A.A. Aleksandrova. Approval of the final version of the article – V.V. Gaynitdinova.
Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: The study was conducted without any sponsorship.
Keywords
bronchial asthma in the elderly
comorbidity
immunosenescence
fixed bronchial obstruction
treatment
About the Authors
Viliya V. Gaynitdinova, Dr. Sci. (Med.), Professor, Department of Pulmonology, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; ivv_08@mail.ru, ORCID: https://orcid.org/0000-0001-9928-926XAlena A. Aleksandrova, Pulmonologist, Central Clinical Hospital with Polyclinic of the Administrative Directorate of the President of the Russian Federation, Moscow, Russia; doc.aleksandrovaalena@mail.ru, ORCID: https://orcid.org/0000-0003-2334-0801 (corresponding author)
Svetlana A. Evdokimova, Cand. Sci. (Med.), Head of the Pulmonology Department, Central Clinical Hospital with Polyclinic of the Administrative Directorate of the President of the Russian Federation, Moscow, Russia; Evdokimovasa@yandex.ru, ORCID: https://orcid.org/0009-0001-3120-0545
Similar Articles
